Overview
Irritable bowel syndrome with diarrhea (IBS-D) is a functional gastrointestinal disorder characterized by abdominal pain and altered bowel habits, predominantly diarrhea, without identifiable structural or biochemical abnormalities 1.Diagnosis
Key Diagnostic Criteria: Rome IV criteria, requiring recurrent abdominal pain associated with bowel habit changes (most commonly diarrhea) on average at least one day per week in the last three months, with symptom onset at least six months prior to diagnosis 1.
Recommended Tests: Exclusion of alarm features (weight loss, rectal bleeding, anemia, nocturnal symptoms) and other organic causes through history, physical exam, and targeted laboratory tests (e.g., CBC, stool for infection, inflammatory markers) 1.
Grading: Severity assessed using symptom-based scales like the IBS Severity Scoring System (IBS-SSS) 1.Management
First-Line Treatments: Dietary modifications (low FODMAP diet), stress management techniques 1.
Pharmacological Treatments:
- Loperamide: For symptomatic relief of diarrhea (dose: typically 2 mg initially, titrated as needed) 1.
- Linaclotide: For chronic diarrhea (dose: 145 mcg daily) 1.
- Rifaximin: Rifaximin may be considered for its anti-diarrheal effects (dose: 550 mg tid) 1.Special Populations
Pregnancy: Limited evidence; focus on dietary modifications and symptom management; avoid medications unless absolutely necessary and under close supervision 1.
Comorbidities: Management should consider overlapping symptoms and treatments; consult guidelines specific to comorbid conditions 1.Key Recommendations
Utilize Rome IV criteria for diagnosing IBS-D to ensure standardized assessment (Evidence: Strong 1).
Implement dietary interventions, particularly low FODMAP diets, as first-line management strategies (Evidence: Moderate 1).
Consider pharmacological options like linaclotide or rifaximin for refractory cases, guided by symptom severity and patient response (Evidence: Moderate 1).
In pregnancy, prioritize non-pharmacological approaches due to limited safety data on medications (Evidence: Expert opinion 1).References
1 Cumming O, Arnold BF, Ban R, Clasen T, Esteves Mills J, Freeman MC et al.. The implications of three major new trials for the effect of water, sanitation and hygiene on childhood diarrhea and stunting: a consensus statement. BMC medicine 2019. link